Ex vivo versus in vivo cell engineering
In one sentence
Ex vivo and in vivo cell engineering differ in whether cells receive their new instructions outside or inside the body.
The intuition
One route sends cells to a laboratory workshop. The other sends an instruction carrier into the body. Both routes need manufacturing. What changes is the product administered and where the patient-specific engineering occurs.
The workshop analogy can make the second route sound effortless. Inside the body, delivery has to find the intended cells amid many others, and the resulting cell population cannot be inspected as a finished bag before dosing.
How it works
In an ex vivo process, cells are collected, engineered and tested outside the body before administration. In an in vivo process, a manufactured delivery product supplies genetic instructions to cells inside the body. The later engineered cells are an outcome of that delivery.
| Question | Ex vivo | In vivo |
|---|---|---|
| What is administered? | A manufactured cell product | A carrier containing genetic instructions |
| Where is cell engineering done? | Laboratory processing | Within the recipient |
| What can be sampled before dosing? | The manufactured cell lot | The carrier lot |
| What needs downstream measurement? | Persistence, behavior and tissue access of infused cells | Cell-type delivery, expression, cell numbers, behavior and tissue access |
Lentiviral vectors and lipid nanoparticles (LNPs) can be used in particular designs. Carrier choice determines additional persistence and safety questions. Engineering location alone does not specify whether the instructions integrate or expression is transient.
Why it matters in cancer
For chimeric antigen receptor (CAR) therapy, delivery targeting addresses the immune cell; cancer targeting belongs to the receptor that cell makes. A correctly addressed delivery product can still install an ineffective or unsafe receptor.
Whose cells are used is another axis. Autologous means the patient's cells; allogeneic means donor cells. A ready-made delivery vial can engineer the patient's own cells. Its manufacturing convenience does not establish clinical equivalence to a tested cell product.
Worked example
A fictional mouse receives laboratory-engineered cells, which then shrink a tumor. The experiment was performed in vivo, but the cells were engineered ex vivo. To resolve a headline, ask what was administered. The phrase “works in vivo” cannot answer that question on its own.
Common confusions
- In vivo testing is different from in vivo engineering.
- Off-the-shelf delivery does not necessarily mean donor-cell therapy.
- Removing cell collection does not remove product manufacturing, quality control or safety monitoring.
- A carrier dose is not a known final number of engineered cells.
Related concepts
Sources and scope
Source check: October 9, 2026. This page explains a method or mechanism. Expert and learner review remain pending.
- Hunter et al., primary targeted RNA delivery study — experimental settings do not establish human solid-tumor efficacy.
- Primary targeted lentiviral delivery study.
- FDA CAR T-cell product-development guidance.